Immune and metabolic research

Best Peptides for Immune Support and Longevity, Ranked by Evidence

This is the category with the most rigorous published evidence on the site, including a meta-analysis and a drug with accelerated FDA approval for a specific rare disease. None of that evidence transfers automatically to general wellness use.

Editorial review: September 14, 2026. Ranked by evidence strength, not popularity.

Jorge Abreu is not a doctor. This is an educational research summary, not a prescription or a personal dosing plan. Study results do not establish that a supplier product is safe or effective for people. Consult a licensed clinician about medical decisions.

Key takeaways

Ranked by what has actually been studied

  • Meta-analysis level evidence, mixed results: Thymosin alpha-1
  • Related drug has accelerated FDA approval: SS-31
  • Broad human trial base, not a peptide: NAD+
  • Anti-inflammatory mechanism, animal stage: KPV
01

Thymosin alpha-1 · Meta-analysis level evidence, mixed results

A sepsis meta-analysis of 11 randomized controlled trials in 967 versus 960 patients reported a significant mortality reduction, but a separate COVID-19 meta-analysis of 9 studies and 5,352 patients found no significant effect. Same compound, different conditions, different results.

Read the Thymosin alpha-1 research guide →
02

SS-31 · Related drug has accelerated FDA approval

Elamipretide, the drug name for this mitochondria-targeted peptide, is approved as Forzinity for Barth syndrome in patients 30kg and over under an accelerated approval pathway. That approval is for a specific rare genetic condition at a defined clinical dose, not a general longevity claim.

Read the SS-31 research guide →
03

NAD+ · Broad human trial base, not a peptide

A coenzyme, not a peptide, with the most human trial data on this list across NAD+ itself and its precursors. Recent tolerability and neurology research is cited on the guide page.

Read the NAD+ research guide →
04

KPV · Anti-inflammatory mechanism, animal stage

A tripeptide fragment of alpha-MSH studied mainly in animal models of colitis and inflammatory skin conditions. Promising mechanism, no human trial in the literature reviewed.

Read the KPV research guide →
Bottom line: SS-31 and thymosin alpha-1 both have real regulatory or meta-analysis evidence behind them, for narrow, specific indications and supervised dosing. That is a different thing from a general research reason to use them.

Reign Peptide · Business disclosure

Research product listings

Jorge Abreu is involved in Reign Peptide. Links to Reign are a business connection, not an independent endorsement. Reign lists these products for laboratory research, not human consumption.

Use the listing to check the labeled identity, amount and available batch documentation. A purity result alone does not verify sterility, clinical suitability or equivalence to a medicine used in a trial.

Names and sizes are product labels, not dosing recommendations. Confirm current details with the seller.